• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Molecular Profiling of Biliary Tract Cancers in African American and Caucasian Patients.非裔美国人和白种人患者胆管癌的分子特征分析
JCO Precis Oncol. 2025 Jan;9:e2400712. doi: 10.1200/PO-24-00712. Epub 2025 Jan 7.
2
KRAS Allelic Variants in Biliary Tract Cancers.胆管癌中的 KRAS 等位基因突变。
JAMA Netw Open. 2024 May 1;7(5):e249840. doi: 10.1001/jamanetworkopen.2024.9840.
3
Genomic Profiling of Biliary Tract Cancers: Comprehensive Assessment of Anatomic and Geographic Heterogeneity, Co-Alterations and Outcomes.胆管癌的基因组分析:解剖学和地理异质性、共改变及预后的综合评估
J Surg Oncol. 2025 Jan 13. doi: 10.1002/jso.28081.
4
Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study.FGFR2/3改变对接受全身化疗的胆道癌患者的预后影响:比特币研究
Eur J Cancer. 2022 May;166:165-175. doi: 10.1016/j.ejca.2022.02.013. Epub 2022 Mar 15.
5
Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations.胆管癌的基因组特征分析确定了驱动基因和易感性突变。
J Hepatol. 2018 May;68(5):959-969. doi: 10.1016/j.jhep.2018.01.009. Epub 2018 Jan 31.
6
The epidemiological trends of biliary tract cancers in the United States of America.美国胆道癌的流行病学趋势。
BMC Gastroenterol. 2022 Dec 29;22(1):546. doi: 10.1186/s12876-022-02637-8.
7
Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract cancers an ideal playground?匹配基因组分子异常与分子靶向药物:胆管癌是否是一个理想的试验场?
Eur J Cancer. 2017 Aug;81:161-173. doi: 10.1016/j.ejca.2017.05.006. Epub 2017 Jun 17.
8
Targeted therapies in advanced biliary tract cancers-a narrative review.晚期胆道癌的靶向治疗:叙述性综述。
Chin Clin Oncol. 2023 Apr;12(2):14. doi: 10.21037/cco-22-93. Epub 2023 Mar 13.
9
Biliary cancer: Utility of next-generation sequencing for clinical management.胆管癌:新一代测序在临床管理中的应用
Cancer. 2016 Dec 15;122(24):3838-3847. doi: 10.1002/cncr.30254. Epub 2016 Sep 13.
10
Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures.胆道癌的临床、基因组和转录组数据分析揭示了特定亚型的免疫特征。
JCO Precis Oncol. 2022 Jun;6:e2100510. doi: 10.1200/PO.21.00510.

本文引用的文献

1
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study.zanidatamab 治疗人表皮生长因子受体 2(HER2)扩增型、不可切除的局部晚期或转移性胆道癌(HERIZON-BTC-01):一项多中心、单臂、2b 期研究。
Lancet Oncol. 2023 Jul;24(7):772-782. doi: 10.1016/S1470-2045(23)00242-5. Epub 2023 Jun 2.
2
Disparities According to Genetic Ancestry in the Use of Precision Oncology Assays.精准肿瘤学检测使用中基于遗传血统的差异
N Engl J Med. 2023 Jan 19;388(3):281-283. doi: 10.1056/NEJMc2213457.
3
Futibatinib for -Rearranged Intrahepatic Cholangiocarcinoma.用于治疗FGFR2重排型肝内胆管癌的futibatinib
N Engl J Med. 2023 Jan 19;388(3):228-239. doi: 10.1056/NEJMoa2206834.
4
The epidemiological trends of biliary tract cancers in the United States of America.美国胆道癌的流行病学趋势。
BMC Gastroenterol. 2022 Dec 29;22(1):546. doi: 10.1186/s12876-022-02637-8.
5
Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures.胆道癌的临床、基因组和转录组数据分析揭示了特定亚型的免疫特征。
JCO Precis Oncol. 2022 Jun;6:e2100510. doi: 10.1200/PO.21.00510.
6
Comparative Genomic Analysis of Intrahepatic Cholangiocarcinoma: Biopsy Type, Ancestry, and Testing Patterns.肝内胆管癌的比较基因组分析:活检类型、血统和检测模式
Oncologist. 2021 Sep;26(9):787-796. doi: 10.1002/onco.13844. Epub 2021 Jun 18.
7
Clinicogenomic Analysis of -Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib.- 后部重排胆管癌的临床基因组分析确定了对培米替尼反应的相关性和耐药机制。
Cancer Discov. 2021 Feb;11(2):326-339. doi: 10.1158/2159-8290.CD-20-0766. Epub 2020 Nov 20.
8
Frequency and Prognostic Value of IDH Mutations in Korean Patients With Cholangiocarcinoma.韩国胆管癌患者异柠檬酸脱氢酶(IDH)突变的频率及预后价值
Front Oncol. 2020 Aug 18;10:1514. doi: 10.3389/fonc.2020.01514. eCollection 2020.
9
Intrahepatic Cholangiocarcinoma: Genomic Heterogeneity Between Eastern and Western Patients.肝内胆管癌:东西方患者之间的基因组异质性
JCO Precis Oncol. 2020 Jun 1;4. doi: 10.1200/PO.18.00414. eCollection 2020.
10
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.ivosidenib 治疗 IDH1 突变、化疗耐药性胆管癌(ClarIDHy):一项多中心、随机、双盲、安慰剂对照、3 期研究。
Lancet Oncol. 2020 Jun;21(6):796-807. doi: 10.1016/S1470-2045(20)30157-1. Epub 2020 May 13.

非裔美国人和白种人患者胆管癌的分子特征分析

Molecular Profiling of Biliary Tract Cancers in African American and Caucasian Patients.

作者信息

Hu Zishuo Ian, Pavlick Dean C, Ross Jeffrey S, Lee Sunyoung S, Eluri Madhulika, Javle Milind

机构信息

MD Anderson Cancer Center, Houston, TX.

Foundation Medicine, Cambridge, MA.

出版信息

JCO Precis Oncol. 2025 Jan;9:e2400712. doi: 10.1200/PO-24-00712. Epub 2025 Jan 7.

DOI:10.1200/PO-24-00712
PMID:39772832
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11723491/
Abstract

PURPOSE

Biliary tract cancers (BTCs) include intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (ECC), and gallbladder cancers. BTCs have a number of genomic alterations, including isocitrate dehydrogenase 1 () mutations, fibroblast growth factor receptor 2 () rearrangements, and amplifications. Therapies targeting these alterations have shown clinical benefit in patients with BTCs in the United States. However, molecular differences between races in BTCs are largely unknown. In particular, the genomic profiles of African American (AA) patients with BTCs have been infrequently reported. We sought to identify key genomic differences between AA and Caucasian patients with BTCs in the United States in the Foundation Medicine and American Association for Cancer Research (AACR) GENIE databases.

METHODS

BTC patients from AA and Caucasian patients from the Foundation Medicine and AACR GENIE databases were retrospectively reviewed. BTCs were divided into ICC, ECC, and GBCs in the Foundation Medicine database. BTCs were divided into cholangiocarcinomas and GBCs in the AACR GENIE database.

RESULTS

The mean age of AA patients with BTCs was lower compared with Caucasians. and alterations were significantly more frequent in AA patients compared with Caucasian patients with BTCs. mutations in Caucasian patients with BTCs were double that of AA patients.

CONCLUSION

The results of this study suggest that significant genomic differences exist between races and warrant further investigation.

摘要

目的

胆道癌(BTCs)包括肝内胆管癌(ICC)、肝外胆管癌(ECC)和胆囊癌。BTCs存在多种基因组改变,包括异柠檬酸脱氢酶1()突变、成纤维细胞生长因子受体2()重排以及扩增。在美国,针对这些改变的疗法已在BTCs患者中显示出临床益处。然而,BTCs种族间的分子差异在很大程度上尚不清楚。特别是,非裔美国(AA)BTCs患者的基因组概况鲜有报道。我们试图在Foundation Medicine和美国癌症研究协会(AACR)的GENIE数据库中确定美国AA和白种人BTCs患者之间的关键基因组差异。

方法

对Foundation Medicine和AACR GENIE数据库中的AA BTC患者和白种人患者进行回顾性分析。在Foundation Medicine数据库中,BTCs分为ICC、ECC和胆囊癌(GBCs)。在AACR GENIE数据库中,BTCs分为胆管癌和GBCs。

结果

与白种人相比,AA BTC患者的平均年龄较低。与白种人BTC患者相比,AA患者中的和改变明显更常见。白种人BTC患者中的突变是AA患者的两倍。

结论

本研究结果表明种族间存在显著的基因组差异,值得进一步研究。